0
Acarix har været en lang ørkenvandring med emissioner og udvanding, men MÅSKE kan dette studie vække kursen igen?
Bestemt ikke nogen anbefaling, men den kan blive interessant, HVIS de begynder at få gang i salget
Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor® System in U.S. Emergency Departments
I dag kl. 09:40 ∙ MFN
Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics -- Open demonstrating that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments.
The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor® System with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings---estimated between $7.3 million and $15.3 million per 10,000 patients---without compromising patient safety.
"This study reinforces what we at Acarix have long known --- that the CADScor® System has the potential to revolutionize the early assessment of chest pain. By delivering fast, reliable results to safely rule out significant coronary artery disease, it helps reduce unnecessary testing and alleviates the burden on emergency departments," said Aamir Mahmood, CEO of Acarix.
Bestemt ikke nogen anbefaling, men den kan blive interessant, HVIS de begynder at få gang i salget
Acarix Applauds New Peer-Reviewed Study Demonstrating Cost-Effectiveness of the CADScor® System in U.S. Emergency Departments
I dag kl. 09:40 ∙ MFN
Malmö, Sweden - Acarix, a leader in non-invasive cardiac diagnostics, is pleased to announce the publication of a new peer-reviewed study in PharmacoEconomics -- Open demonstrating that the CADScor® System is a cost-effective diagnostic tool for evaluating low-risk chest pain patients in U.S. emergency departments.
The independent study, conducted by researchers from the Baim Institute for Clinical Research and leading academic hospitals in Boston, utilized a comprehensive economic model to compare the CADScor® System with traditional noninvasive cardiac imaging methods. Results showed that a "CADScor-First" strategy could lead to substantial cost savings---estimated between $7.3 million and $15.3 million per 10,000 patients---without compromising patient safety.
"This study reinforces what we at Acarix have long known --- that the CADScor® System has the potential to revolutionize the early assessment of chest pain. By delivering fast, reliable results to safely rule out significant coronary artery disease, it helps reduce unnecessary testing and alleviates the burden on emergency departments," said Aamir Mahmood, CEO of Acarix.
26/6 2025 10:07 LP90 0127021 det er da at håbe det har været lidt af en dødsejler længe jeg har en del aktier i den
26/6 2025 10:20 Aps invest 1127023 En MEGET stor dødsejler, hvor der intet er sket i vel efterhånden 10 år :( Lad os håbe de snart får det gennembrud vi har ventet på MEGET længe :)
10/7 2025 19:51 Aps invest 0127163 Fra 0,29 d 26/6 til 0,42......trods en ørkenvandring ....ca. 50% op på omkring 14 dage....så det kan gå rigtig stærkt HVIS gennembruddet kommer......INGEN anbefaling :)
16/7 2025 15:24 Aps invest 0127242 Det lysner med denne nyhed, men håbet har været der mange gange de sidste 10 år, men aldrig det helt STORE gennembrud. INGEN anbefaling :)
Nyhed fra 8 juli.... Acarix Enters MENA Region with First Major Order, Expanding Global Presence
8 jul. 16:05 ∙ MFN
Malmö, Sweden -- July 8, 2025 -- Acarix, a global pioneer in AI-driven and acoustics-based cardiac diagnostics, is proud to announce its first order in the Middle East and North Africa (MENA) region. Valued at 1.35M SEK, this order from a leading regional distributor represents a significant step in Acarix's international expansion strategy.
This milestone marks Acarix's official entry into one of the world's most dynamic healthcare markets, underscoring the growing global demand for its innovative diagnostic solutions aimed at improving early detection of coronary artery disease.
Nyhed fra 8 juli.... Acarix Enters MENA Region with First Major Order, Expanding Global Presence
8 jul. 16:05 ∙ MFN
Malmö, Sweden -- July 8, 2025 -- Acarix, a global pioneer in AI-driven and acoustics-based cardiac diagnostics, is proud to announce its first order in the Middle East and North Africa (MENA) region. Valued at 1.35M SEK, this order from a leading regional distributor represents a significant step in Acarix's international expansion strategy.
This milestone marks Acarix's official entry into one of the world's most dynamic healthcare markets, underscoring the growing global demand for its innovative diagnostic solutions aimed at improving early detection of coronary artery disease.
